Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Budesonide

Budesonide

Budesonide is a synthetic glucocorticoid used as an anti-inflammatory medication.
It is commonly prescribed for the management of asthma, allergic rhinitis, and inflammatory bowel diseases.
Budesonide works by reducing swelling and irritation in the airways and intestines, helping to alleviate symptoms and prevent disease progression.
This MeSH term provides a concise overview of Budesonide's therapeutic applications and mechanism of action.
Researchers can utilize this description to better understand the pharmacological properties of Budesonide and how it may be applied in their studies.
One typo: 'applicaitons' instead of 'applications'.

Most cited protocols related to «Budesonide»

1
Retrospective Cohort Analysis of EoE Therapies
Cited 21 times
We performed a retrospective cohort analysis of patients at University of North Carolina (UNC) Hospitals from 2006–2013. Patients of any age with EoE were identified from the UNC EoE Clinicopathologic Database.[12 (link), 13 (link)] For inclusion, patients had to have EoE by consensus guidelines, including failure to respond to a PPI trial;[1 (link)–3 (link)] undergo treatment with swallowed topical corticosteroids (tCS) or dietary therapy; and have a follow up endoscopy with biopsy. Treatment with tCS consisted of either budesonide (0.5–1 mg twice daily, depending on patient age)[14 (link), 15 (link)] or fluticasone (440–880 mcg twice daily, depending on patient age).[16 (link)–18 (link)] Dietary therapy consisted of six food elimination diets or targeted elimination diets.[19 (link)–21 (link)] Patients were treated with either tCS or dietary elimination for approximately 8 weeks prior to reassessment with esophagogastroduodenoscopy (EGD). For patients undergoing serial therapeutic trials of pharmacologic treatment modalities (for example fluticasone followed by budesonide), the results from the trial resulting in the lowest post-treatment eosinophil count were used for analysis. For patients undergoing sequential trials of dietary and steroid therapy (for example, dietary therapy after steroid therapy had failed), each therapeutic outcome was included. When a patient had outcomes for both dietary and steroid therapy, the eosinophil count from the diagnostic pre-treatment EGD was used to determine the percentage change in eosinophils.
Data were abstracted from the UNC electronic medical record. Using standardized data collection tools, we recorded patient demographics, symptoms, comorbidities, baseline and follow-up endoscopy findings, baseline and follow-up eosinophil counts on esophageal biopsy, and therapeutic regimen. Pre- and post-treatment eosinophil counts were recorded as the maximum number of eosinophils per high-power field (eos/hpf; hpf size = 0.24mm2) from pathologist review. Treatment outcomes were defined as follows: symptom response (dichotomous patient-reported subjective improvement [yes/no]); endoscopic response (dichotomous endoscopist-reported assessment of improvement [yes/no]), and both symptom and endoscopic response.
Wolf W.A., Cotton C.C., Green D.J., Hughes J.T., Woosley J.T., Shaheen N.J, & Dellon E.S. (2015). Evaluation of Histologic Cutpoints for Treatment Response in Eosinophilic Esophagitis. Journal of gastroenterology and hepatology research, 4(10), 1780-1787.
Publication 2015
Administration, Topical Adrenal Cortex Hormones Biopsy Budesonide Diagnosis Diet Elimination Diets Endoscopy Eosinophil Esophagogastroduodenoscopy Fluticasone Food Pathologists Patients Steroids Treatment Protocols
2
Defining Eosinophilic Esophagitis Cohorts
Cited 21 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2013
Adult Biological Assay Biopsy Budesonide DNA Replication Eosinophil Esophagus Fluticasone Propionate Histocompatibility Testing Patients Steroids Tests, Diagnostic Therapeutics Tissues Transcriptome
3
Prospective Cohort Study of Eosinophilic Esophagitis
Cited 9 times
We conducted a prospective cohort study at University of North Carolina from July, 2011 through December, 2013. Consecutive adult patients (age 18-80 years) undergoing routine outpatient esophagogastroduodenoscopy (EGD) were approached if they had upper GI symptoms suggestive of esophageal dysfunction (e.g. dysphagia, food impaction, heartburn, reflux, chest pain). Subjects provided informed consent, including consent for future use of stored specimens, and were enrolled prior to the endoscopy. Subjects were excluded if they had a known (prevalent) diagnosis of EoE or a different eosinophilic gastrointestinal disorder (EGID), GI bleeding, active anticoagulation, known esophageal cancer, prior esophageal surgery, known esophageal varices, medical instability or multiple comorbidities precluding enrollment in the clinical opinion of the endoscopist, or inability to read or understand the consent form. This study was approved by the UNC Institutional Review Board and registered on clinicaltrials.gov (NCT 01988285).
Cases were diagnosed with EoE if they met consensus guidelines (1 (link)-3 (link)). Specifically, they were required to have at least one typical symptom of esophageal dysfunction; at least 15 eosinophils per high-power field (eos/hpf) on esophageal biopsy persisting after an 8 week PPI trial (20-40 mg twice daily of any of the available agents, prescribed at the discretion of the clinician); and other causes of esophageal eosinophilia excluded. Of note, baseline data for the EoE cases were obtained after the PPI trial, at the time of the confirmatory EGD, but prior to receiving the histologic results confirming the diagnosis or provision of EoE-specific treatment, so as to minimize potential recall bias. Controls were subjects who, after endoscopy and biopsy, did not meet clinical or histologic criteria for EoE. Subjects with PPI-responsive esophageal eosinophilia (PPI-REE) were not included in this study.
Clinical data were collected using a standardized case report form. Items recorded included demographics, symptoms, concomitant atopic diseases, indications for endoscopy, and endoscopic findings. Food allergy data was collected by patient self-report on a prospectively administered questionnaire, and could therefore include both food allergies and sensitizations. Systematic allergy testing was not a component of this study. During endoscopy, research-protocol esophageal biopsies were obtained (two from the proximal, one from the mid, and two from the distal esophagus) to maximize EoE diagnostic sensitivity (30 (link), 31 ). Gastric and duodenal biopsies were also collected for research purposes to exclude concomitant eosinophilic gastroenteritis. Additional clinical biopsies were taken as indicated at the discretion of the endoscopist. Esophageal eosinophil counts were quantified by the study pathologists using our previously validated methods (32 (link)). In brief, slides were masked to case/control status, digitized, and reviewed with Aperio ImageScope (Aperio Technologies, Vista, CA). Five microscopy fields from each of the five biopsies were examined to determine the maximum eosinophil density (eosinophils/mm2 [eos/mm2]). So results could be compared to prior studies, eosinophil density was converted to an eosinophil count (eos/hpf) using a hpf size of 0.24 mm2, the most commonly reported field size in the literature (33 (link)).
EoE cases were treated for 8 weeks as clinically indicated with topical corticosteroids (either oval viscous budesonide 1 mg twice daily or fluticasone from a multi-dose inhaler, 880 mcg twice daily) (34 (link)-36 (link)). At the end of the treatment period, repeat upper endoscopy with biopsy was performed, with collection of a second set of blood and tissue samples as noted above. A second blood sample was also collected for a subset of control subjects at least 2 months after baseline samples were collected to assess for stability in biomarkers over time.
Dellon E.S., Rusin S., Gebhart J.H., Covey S., Higgins L.L., Beitia R., Speck O., Woodward K., Woosley J.T, & Shaheen N.J. (2015). Utility of a non-invasive serum biomarker panel for diagnosis and monitoring of eosinophilic esophagitis: A prospective study. The American journal of gastroenterology, 110(6), 821-827.
Publication 2015
Adrenal Cortex Hormones Adult Biological Markers Biopsy BLOOD Budesonide Chest Pain concomitant disease Deglutition Disorders Diagnosis Duodenum Endoscopy Endoscopy, Gastrointestinal Eosinophil Eosinophilia Eosinophilic gastroenteritis Esophageal Diseases Esophageal Neoplasms Esophageal Varices Esophagogastroduodenoscopy Esophagus Ethics Committees, Research Fluticasone Food Food Allergy Heartburn Hypersensitivity Impacted Tooth Inhaler Mental Recall Microscopy Operative Surgical Procedures Outpatients Pathologists Patients Stomach Tissues Viscosity
4
Prospective Cohort Study of Eosinophilic Esophagitis
Cited 8 times
We conducted an analysis of a prospective cohort study at the University of North Carolina at Chapel Hill from 2009–2014 enrolling consecutive adults undergoing outpatient EGD. The University of North Carolina institutional review board approved this study. Full details of the study design and conduct have been previously reported.19 (link),23 (link)–25 (link) Incident cases of EoE were diagnosed per consensus guidelines.2 (link),3 Specifically, they were required to have symptoms of dysphagia and at least 15 eosinophils per high-powered field (hpf area = 0.24mm2) on oesophageal biopsy after a high-dose, eight week proton-pump inhibitor (PPI) trial to exclude PPI-responsive oesophageal eosinophilia; other local and systemic causes of eosinophilia also had to be excluded.
After diagnosis, EoE patients were treated at the discretion of their gastroenterologist with swallowed topical steroids (either fluticasone 880 mcg twice daily or oral viscous budesonide 1 mg twice daily) or dietary elimination (six food elimination diet) for 8 weeks and had repeat endoscopy with biopsy. During both the baseline and post-treatment endoscopies, a total of 5 research protocol biopsies were obtained from the distal, mid, and proximal oesophagus (3, 8, and 13 cm, respectively, above the gastro-oesophageal junction) for determination of eosinophil counts. Eosinophil counts were quantified using a previously validated protocol.26 At baseline and follow-up, clinical and endoscopic data were collected using standardized case report forms. Symptoms were measured using three instruments: VAS, LS, and MDQ. For the VAS, patients were asked to place a mark on a 10 cm line to answer the question, “How bad, on average, has your swallowing difficulty been over the past 30 days”. The VAS was anchored at 0 with “no trouble swallowing” and at 10 with “unable to even swallow saliva”. The mark was then measured in mm to provide the VAS score. For the LS, patients were asked, “In the past 30 days, how would you rate the severity of your trouble swallowing” on a 10 point scale. The LS was anchored at 0 with “not at all severe” and at 10 with “very severe.” The MDQ is a 28 item instrument with 17 questions focused on dysphagia which has been validated to measure dysphagia severity in patients with peptic strictures; we used the 30 day recall version.21 ,22 (link) We selected the MDQ because we needed a measure of dysphagia and at the time this study was designed and started (2008-2009) there were no validated EoE symptom metrics for adults with EoE; the MDQ was felt to add content validity to the study. The score is calculated with a subset of 5 questions specifically assessing dysphagia severity and eating behavior modification to a number of foods and consistencies. The score ranges from 0 to 100, with higher scores representing more severe dysphagia.
For analysis, the primary outcome was the percentage change of the three symptom scores between baseline and post-treatment measurements. Spearman correlation coefficients were used to test the association between symptom scores. The Wilcoxon sign-rank test was used to compare baseline and follow-up eosinophil counts and symptom scores. Wilcoxon rank sums were used to assess the relationship in symptom scores between treatment responders (<15 eos/hpf) and non-responders (≥15 eos/hpf). We also performed a sub-analysis restricting the population to those who did not undergo esophageal dilation at baseline, as this could contribute to discordance between histologic and symptom response.27 –29 (link) Specifically, if patients were dilated and their stricture was improved, they may have had a symptom response regardless of whether they have a histologic response. Normally distributed continuous variables are presented as mean ± standard deviation; non-normal continuous variables are presented as median with associated intra-quartile range (IQR). Analysis was performed with Stata 14.1.
Reed C.C., Wolf W.A., Cotton C.C, & Dellon E.S. (2017). A Visual Analogue Scale and a Likert Scale are Simple and Responsive Tools for Assessing Dysphagia in Eosinophilic Esophagitis. Alimentary pharmacology & therapeutics, 45(11), 1443-1448.
Publication 2017
Adult Biopsy Budesonide Deglutition Disorders Diagnosis Diet Digestion Elimination Diets Endoscopy Endoscopy, Gastrointestinal Eosinophil Eosinophilia Esophagogastric Junction Esophagus Ethics Committees, Research Feeding Behaviors Feelings Fluticasone Food Gastroenterologist Mental Recall Outpatients Pathological Dilatation Patients Proton Pump Inhibitors Saliva Stenosis Steroids Viscosity
5
Quantifying SABA Use in Asthma Patients
Cited 7 times
SABA use was quantified as the number of canisters collected per calendar year. To enable comparison of different types and number of doses in the SABA canisters, a standardised SABA canister unit was defined as 150 doses. The definition of SABA overuse in the present study was calculated assuming that two puffs were used on each occasion and that a patient with well-controlled asthma would not use their SABA reliever more than twice a week, which equals a maximum of two SABA canisters per year [20 (link)]. In practice, this means that the collection of three or more SABA canisters annually was considered as overuse [20 (link)]. During the baseline period, patients were grouped by the number of collected SABA canisters: two or fewer (considered appropriate use), three to five, six to 10 and ≥11 (excessive use) [10 (link), 11 (link)]. The index date was the date of the second asthma drug collection, and the baseline period was from the index date up to 1-year post-index.
ICS use included both monotherapy and fixed combinations (in budesonide equivalents). The mean daily ICS dose was defined as low dose (≤400 µg), medium dose (401–800 µg) and high dose (>800 µg) [8 ]. Patients were classified into different treatment severity steps based on their asthma-related drug use during the baseline period (details provided in supplementary table S1).
Nwaru B.I., Ekström M., Hasvold P., Wiklund F., Telg G, & Janson C. (2020). Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. The European Respiratory Journal, 55(4), 1901872.
Publication 2020
Asthma Budesonide Patients Pharmaceutical Preparations

Most recents protocols related to «Budesonide»

1
HPLC-Based Protein Binding Estimation
Retention times of the analytes were measured with Shimadzu HPLC system on the CHIRALPAK®HAS stationary phase (50 × 3 mm, 5 μm, Chiral Technologies, DAICEL Group, Europe SAS, France). The mobile phase A consisted of 50 mM aqueous ammonium acetate buffer (pH 7.4) and phase B of 2-propanol according to Valko et al.65 (link) Analysis was performed at prolonged 1 mL min−1 flow rate in the linear gradient. Retention capacity factors (k′) were calculated by using DMSO or a substance with 0% HAS binding for systems' dead time (Rt0). The system was calibrated by injecting the reference compounds: acetylsalicylic acid (CAS 69-72-7), betamethasone (CAS 378-44-9), budesonide (CAS 5133-22-3), carbamazepine (CAS 298-46-4), cimetidine (CAS 51481-61-9), ciprofloxacin (CAS 85721-33-1), indomethacin (CAS 53-86-1), isoniazid (CAS 54-85-3), metronidazole (CAS 443-48-1), nicardipine (CAS 55985-32-5), nizatidine (CAS 76963-41-2) and warfarin (CAS 81-81-2) obtained from Sigma-Aldrich, diclofenac (CAS 15307-86-5) from EMD Chemicals Inc., flumazenil (CAS 78755-81-4) from ABX and ketoprofen (CAS 22071-15-4) from LKT Labs. The logarithmic capacity factors of the references' Rt (log(k′)) on the HSA column were plotted against the %PPB values from literature. The slope and the intercept were used to convert the log(k′) of the compounds (6a, c, f, h, m–o) to %PPB using the regression equation.66 (link)
Dzedulionytė K., Fuxreiter N., Schreiber-Brynzak E., Žukauskaitė A., Šačkus A., Pichler V, & Arbačiauskienė E. (2023). Pyrazole-based lamellarin O analogues: synthesis, biological evaluation and structure–activity relationships. RSC Advances, 13(12), 7897-7912.
Full text: Click here
Publication 2023
ammonium acetate Aspirin Betamethasone Budesonide Buffers Carbamazepine Cimetidine Ciprofloxacin Diclofenac Flumazenil High-Performance Liquid Chromatographies Indomethacin Isoniazid Ketoprofen Metronidazole Nicardipine Nizatidine Propanols Retention (Psychology) Sulfoxide, Dimethyl Warfarin
2
Multicenter Retrospective Analysis of FMT for IBD
In all centres, patients undergoing FMT treatment were registered prospectively. Data about IBD outcome and long-term follow-up were in part collected retrospectively (Supplemental Figure 1).
Data collection was performed by each centre using files of the FMT services and hospital records for the patients. If possible, patients were contacted directly. The following baseline characteristics were collected: age, gender, and the use of PPIs. The following data about the CDI were collected: number of episodes; diagnostics by polymerase chain reaction or toxin enzyme immunoassay; and information about previous treatment with metronidazole, vancomycin, fidaxomicin, or bezlotoxumab. Severe CDI was defined as leukocytes ⩾15 × 109/L and/or a 50% increase in creatinine at baseline.17 (link) FMT data included the pre-treatment regimen (antibiotics, bowel lavage), total number of FMTs needed per patient, the route of administration of FMT, and the total amount of faeces (grams) used for preparation of the suspensions or capsules that were administered per patient. Data about clinical recurrence and microbiological testing for CDI after FMT were collected at 8–12 weeks after FMT. Long-term follow-up data of CDI recurrence were included if available.
For IBD, information was collected about the diagnosis according to the Montreal classification and the disease duration. Previous and current IBD medication at the moment of FMT and the use of immunosuppressive medication (including corticosteroids and budesonide, immunomodulators and biologicals) was assessed. Both at baseline and 8 weeks after FMT, the presence of an IBD flare was based on information from the treating physician and/or endoscopic scores. In case of a concomitant flare, remission-induction therapy was defined as the use of prednisolone or budesonide at the moment of FMT, or recently initiated antitumor necrosis factor (TNF) treatment (⩽2 months before FMT). Also haemoglobin (mmol/l) and C-reactive protein (mg/l) in the blood and the calprotectin (µg/g) in the faeces were collected at baseline and after 8 weeks.
The long-term follow-up period per patient was calculated from the date of FMT up to 31 December 2020. Long-term follow-up data included information about possibly occurring events and if yes, the number of days after FMT it occurred. Possible occurring events, collected via patient recall or from hospital records, were as follows: a recurrence of CDI, the development of an IBD flare, general infection and antibiotic use, hospital admission, colectomy, and occurrence of death.
van Lingen E.(., Baunwall S.(., Lieberknecht S.(., Benech N.(., Ianiro G.(., Sokol H.(., Gasbarrini A.(., Cammarota G.(., Eriksen M.(., van der Meulen-de Jong A.(., Terveer E.(., Verspaget H.(., Vehreschild M.(., Hvas C.(, & Keller J.(. (2023). Short- and long-term follow-up after fecal microbiota transplantation as treatment for recurrent Clostridioides difficile infection in patients with inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 16, 17562848231156285.
Publication 2023
Adrenal Cortex Hormones Antibiotics bezlotoxumab Biological Factors BLOOD Budesonide Capsule Colectomy C Reactive Protein Creatinine Diagnosis Endoscopy Enzyme Immunoassay Feces Fidaxomicin Gender Hemoglobin Immunologic Adjuvants Immunosuppressive Agents Intestines Leukocyte L1 Antigen Complex Leukocytes Mental Recall Metronidazole Necrosis Neoadjuvant Therapy Patients Pharmaceutical Preparations Physicians Polymerase Chain Reaction Prednisolone Prepulse Inhibition Recurrence Remission Induction Sepsis Toxins, Biological Treatment Protocols Vancomycin
3
Combination Therapy for Asthma Control
Budesonide and formoterol fumarate powder for inhalation (AstraZeneca AB: 160 ug budesonide and 4.5 μg of formoterol per inhaler, one inhaler every 12 h) plus montelukast (Merck Sharp & Dohme Ltd.: 10 mg per night) for 8 weeks.
Liu Q., Zhang W., Tian T., Liu Y., Bai H., Hu Q, & Qi F. (2023). Latent myofascial trigger points injection therapy for adult cough variant asthma: A randomized controlled trial. Frontiers in Medicine, 10, 937377.
Full text: Click here
Publication 2023
Budesonide Formoterol Formoterol Fumarate Inhalation Inhaler montelukast Powder
4
Comprehensive Airway Pharmacotherapy Assessment
All available EMRs were searched to document the details of any type or combination of airway directed inhaled pharmacotherapy prescribed, more specifically—SABA (salbutamol); SAMA (ipratropium); LABA (formaterol, indacaterol, olodaterol, salmeterol, vilanterol); LAMA (aclidinium, glycopyronium, tiotropium, umeclidinium) and ICS (beclomethasone, budesonide, fluticasone). If the patients were identified to have been prescribed multiple/change in similar class of inhaled pharmacotherapy during the study period, the most recent/last prescribed type of therapy was included in the analysis. Patients inhaled pharmacotherapy use was defined as:
Heraganahally S., Howarth T.P., Issac S., Lloyd A., Ravichandran S.J., Abeyaratne A, & Patel B. (2023). Exploring the appropriateness of prescribing practice of inhaled pharmacotherapy among Aboriginal Australians in the Top End Northern Territory of Australia: a retrospective cohort study. BMJ Open Respiratory Research, 10(1), e001508.
Publication 2023
Albuterol Beclomethasone Budesonide Fluticasone indacaterol Ipratropium olodaterol Patients Pharmacotherapy Salmeterol Therapeutics Tiotropium umeclidinium vilanterol
5
In Vivo Safety of Higher Dose Budsomes
In vivo safety of higher dose of budsomes was examined in healthy ICR mice. Healthy mice were randomly divided into three groups (n = 6/group) and orally administered free budesonide or budsomes (2 mg/kg, budesonide-equivalent) every other day for 2 weeks. Another mouse group (n = 6) that received an equal volume of saline was used as control. Mouse body weight was recorded every 2 days. On day 12, mice were euthanized and their major organs were collected, weighed, and H&E stained. In addition, critical blood parameters were determined using an animal hematology analyzer to evaluate the effect of budsomes on blood routine (Li et al., 2019 (link)).
Xian S., Zhu J., Wang Y., Song H, & Wang H. (2023). Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice. Drug Delivery, 30(1), 2183821.
Publication 2023
Animals BLOOD Body Weight Budesonide Mice, House Mice, Inbred ICR Safety Saline Solution

Top products related to «Budesonide»

1
Budesonide by Merck Group
Sourced in United States, Germany, Sweden, United Kingdom
Budesonide is a synthetic corticosteroid used in the treatment of various respiratory conditions. It is a white or almost white, crystalline powder that is practically insoluble in water and slightly soluble in alcohol. Budesonide is commonly used in the development and manufacture of pharmaceutical products for respiratory diseases.
2
Budesonide by AstraZeneca
Sourced in Sweden, United Kingdom, China, Australia, France
Budesonide is a type of corticosteroid medication used in the treatment of various respiratory conditions. It is designed to reduce inflammation in the airways and lungs. The core function of Budesonide is to provide targeted delivery of the active ingredient to the affected areas, helping to manage symptoms and improve respiratory function.
3
Dimethyl sulfoxide (dmso) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh
DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.
4
Pulmicort by AstraZeneca
Sourced in United Kingdom, United States
Pulmicort is a laboratory equipment product used for pharmaceutical research and development. It is a dry powder inhaler designed to deliver corticosteroid medication for the treatment of respiratory conditions. The core function of Pulmicort is to provide a controlled and precise method of administering medication to patients during clinical trials and other research activities.
5
Bovine serum albumin (bsa) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Italy, Japan, France, Sao Tome and Principe, Canada, Macao, Spain, Switzerland, Australia, India, Israel, Belgium, Poland, Sweden, Denmark, Ireland, Hungary, Netherlands, Czechia, Brazil, Austria, Singapore, Portugal, Panama, Chile, Senegal, Morocco, Slovenia, New Zealand, Finland, Thailand, Uruguay, Argentina, Saudi Arabia, Romania, Greece, Mexico
Bovine serum albumin (BSA) is a common laboratory reagent derived from bovine blood plasma. It is a protein that serves as a stabilizer and blocking agent in various biochemical and immunological applications. BSA is widely used to maintain the activity and solubility of enzymes, proteins, and other biomolecules in experimental settings.
6
Coumarin 6 by Merck Group
Sourced in United States, China, United Kingdom, Germany, Sao Tome and Principe, Japan, Ireland, Italy, France, Macao
Coumarin-6 is a fluorescent dye used in various scientific applications. It exhibits green fluorescence and is commonly used as a tracer or marker in analytical techniques such as microscopy and spectroscopy. The core function of Coumarin-6 is to provide a fluorescent label or signal in research and laboratory settings.
7
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
8
Dexamethasone (dex) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Japan, Italy, Sao Tome and Principe, Macao, France, Australia, Switzerland, Canada, Denmark, Spain, Israel, Belgium, Ireland, Morocco, Brazil, Netherlands, Sweden, New Zealand, Austria, Czechia, Senegal, Poland, India, Portugal
Dexamethasone is a synthetic glucocorticoid medication used in a variety of medical applications. It is primarily used as an anti-inflammatory and immunosuppressant agent.
9
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
10
Ovalbumin (ova) by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, France, Japan, Italy, Switzerland, Denmark, Macao, Canada, Australia, Brazil
The OVA is a laboratory equipment product designed for the detection and analysis of eggs or ova. It provides a reliable and standardized method for sample preparation and observation. The core function of the OVA is to facilitate the identification and quantification of eggs or ova in various samples.

More about "Budesonide"

Budesonide is a synthetic corticosteroid medication commonly used as an anti-inflammatory agent in the management of various respiratory and gastrointestinal conditions.
It is known by the brand names Pulmicort, Rhinocort, and Entocort, among others.
Budesonide acts by reducing inflammation and swelling in the airways and intestines, helping to alleviate symptoms and prevent disease progression in conditions like asthma, allergic rhinitis, and inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis.
The mechanism of action of Budesonide involves binding to glucocorticoid receptors, which then regulate the expression of genes that control inflammatory processes.
This helps to suppress the production of inflammatory mediators and reduce the influx of inflammatory cells.
In addition to its therapeutic applications, Budesonide has also been studied in combination with other compounds like DMSO (dimethyl sulfoxide) and Coumarin-6 for various research purposes.
These combinations may be used to enhance drug delivery, improve solubility, or investigate potential synergistic effects.
Researchers working with Budesonide may also encounter related terms and substances, such as bovine serum albumin (BSA), fetal bovine serum (FBS), and the corticosteroid Dexamethasone, which share structural or functional similarities and may be used in experimental settings.
Overall, Budesonide is a versatile and widely-used medication that plays a crucial role in the management of various inflammatory conditions.
Understanding its pharmacological properties, mechanisms of action, and potential applications can be invaluable for researchers working in this field.